FDx Advisors’s Sarepta Therapeutics SRPT Stock Holding History

FDx Advisors’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-1,540	Closed	-$249K	–	785
2018 Q3	$249K	Buy	+1,540	New	+$211K	0.01%	771

Other funds holding SRPT

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

FAM

Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

FDx Advisors's SRPT Position: Q4 2018 in Review

FDx Advisors sold out of Sarepta Therapeutics (SRPT) in Q4 2018, closing a stake of 1,540 shares — an estimated $249K sold.

FDx Advisors first reported a position in SRPT in Q3 2018 and held it in 1 quarter. The position peaked at $249K in Q3 2018. 336 funds tracked by Wall St. Rank hold SRPT as of Q4 2018.

FDx Advisors reported no remaining Sarepta Therapeutics position as of Q4 2018 after selling out during the quarter.
FDx Advisors sold 1,540 Sarepta Therapeutics shares in Q4 2018, an estimated $249K.
FDx Advisors first reported a position in Sarepta Therapeutics in Q3 2018 and held it in 1 quarter.
FDx Advisors's Sarepta Therapeutics position peaked at $249K in Q3 2018.
336 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q4 2018.

Based on FDx Advisors's 13F filing for Q4 2018, filed 7 Feb 2019.